Follow the people · Insider
Christopher John Kenney
Christopher John Kenney files insider transactions with the SEC as a chief medical officer of Xenon Pharmaceuticals (XENE). We hold 3 disclosed purchases and sales filed since 25 August 2021, 1 of them in the last 90 days.
- Files forXENE
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure31 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 23 August 2021 — 28 August 2026Chief Medical Officer · Xenon Pharmaceuticals (XENE)28 Form 4 lines · source: SEC Form 4
Everything they disclosed
28 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 6,368 shares of Xenon PharmaceuticalsSEC Form 431 August 2026Common Shares · traded 28 August 2026 · filed 31 August 2026
- ▼ sold on the open market 700 shares of Xenon PharmaceuticalsSEC Form 431 August 2026Common Shares · traded 28 August 2026 · filed 31 August 2026
- exercised options over 3,750 shares of Xenon PharmaceuticalsSEC Form 413 March 2026Common Shares · traded 12 March 2026 · filed 13 March 2026
- ▼ sold on the open market 1,410 shares of Xenon PharmaceuticalsSEC Form 413 March 2026Common Shares · traded 13 March 2026 · filed 13 March 2026
- exercised options over 3,750 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 413 March 2026Restricted Share Units · traded 12 March 2026 · filed 13 March 2026
- exercised options over 3,750 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 413 March 2026Restricted Share Units · traded 12 March 2026 · filed 13 March 2026
- exercised options over 3,750 shares of Xenon PharmaceuticalsSEC Form 413 March 2026Common Shares · traded 12 March 2026 · filed 13 March 2026
- ▼ sold on the open market 1,410 shares of Xenon PharmaceuticalsSEC Form 413 March 2026Common Shares · traded 13 March 2026 · filed 13 March 2026
- exercised options over 7,500 shares of Xenon PharmaceuticalsSEC Form 411 March 2026Common Shares · traded 9 March 2026 · filed 11 March 2026
- ▼ sold on the open market 2,771 shares of Xenon PharmaceuticalsSEC Form 411 March 2026Common Shares · traded 10 March 2026 · filed 11 March 2026
- was granted 7,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 411 March 2026Performance Share Units · traded 9 March 2026 · filed 11 March 2026
- was granted 7,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 411 March 2026Performance Share Units · traded 9 March 2026 · filed 11 March 2026
- exercised options over 7,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 411 March 2026Performance Share Units · traded 9 March 2026 · filed 11 March 2026
- exercised options over 7,500 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 411 March 2026Performance Share Units · traded 9 March 2026 · filed 11 March 2026
- exercised options over 7,500 shares of Xenon PharmaceuticalsSEC Form 411 March 2026Common Shares · traded 9 March 2026 · filed 11 March 2026
- ▼ sold on the open market 2,771 shares of Xenon PharmaceuticalsSEC Form 411 March 2026Common Shares · traded 10 March 2026 · filed 11 March 2026
- was granted 100,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 49 January 2026Share Option (Right to Buy) · traded 9 January 2026 · filed 9 January 2026
- was granted 20,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 49 January 2026Restricted Share Units · traded 9 January 2026 · filed 9 January 2026
- was granted 100,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 49 January 2026Share Option (Right to Buy) · traded 9 January 2026 · filed 9 January 2026
- was granted 20,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 49 January 2026Restricted Share Units · traded 9 January 2026 · filed 9 January 2026
- was granted 80,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 413 March 2025Share Option (Right to Buy) · traded 12 March 2025 · filed 13 March 2025
- was granted 15,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 413 March 2025Restricted Share Units · traded 12 March 2025 · filed 13 March 2025
- was granted 100,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 412 March 2024Stock Option (Right to Buy) · traded 11 March 2024 · filed 12 March 2024
- ▼ sold on the open market 700 shares of Xenon PharmaceuticalsSEC Form 424 March 2023Common Shares · traded 24 March 2023 · filed 24 March 2023
- was granted 120,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 414 March 2023Stock Option (Right to Buy) · traded 10 March 2023 · filed 14 March 2023
- was granted 125,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 414 March 2022Stock Option (Right to Buy) · traded 10 March 2022 · filed 14 March 2022
- ▲ bought on the open market 700 shares of Xenon PharmaceuticalsSEC Form 421 January 2022Common Shares · traded 21 January 2022 · filed 21 January 2022
- was granted 150,000 shares of Xenon Pharmaceuticals (a derivative holding)SEC Form 425 August 2021Stock Option (Right to Buy) · traded 23 August 2021 · filed 25 August 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.